BMO Capital Maintains Outperform on Disc Medicine, Lowers Price Target to $100

Disc Medicine, Inc. +1.66%

Disc Medicine, Inc.

IRON

60.75

+1.66%

BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ: IRON) with a Outperform and lowers the price target from $120 to $100.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via